Robert E. Gagnon Appointed to Bone Biologics Board of Directors

Bone Biologics Corporation has named Robert E. Gagnon to its Board of Directors, succeeding Erick Lucera. The number of board members remains at four.
 
Gagnon is currently chief financial officer (CFO) of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RNA processing to address hard-to-drug disease drivers.
 
“We are delighted that a professional of Rob’s stature has agreed to join our board of directors,” Bone Biologics President/CEO Jeffrey Frelick stated. “He has supported the growth of so many successful companies and we look forward to Rob’s counsel. His experiences with clinical stage companies, capital raising, and commercial organizations will be particularly valuable as we undertake our pilot study with NB-1.”
 
Gagnon has more than 20 years of financial and commercial experience leading global finance operations. He was an operating partner at Gurnet Point Capital, a healthcare venture capital and private equity fund, and was chief business officer and CFO at Verastem Oncology. Before that, he worked as CFO at Harvard Bioscience Inc. Gagnon also served as executive vice president, CFO, and treasurer at Clean Harbors Inc. as well as chief accounting officer and controller at Biogen Idec Inc. Gagnon served in various senior positions at Deloitte & Touche and PricewaterhouseCoopers.

Gagnon earned an MBA from the MIT Sloan School of Management and a bachelor of arts degree in accounting from Bentley College.
 
Gagnon currently serves on the boards of Verastem Oncology and Purple Biotech.
 
Bone Biologics was founded to pursue regenerative medicine for bone. The Burlington, Mass.-based company is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.